Ruben Mesa, MD, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.
Ruben Mesa, MD, director of Mays Cancer Center, home to UT Health San Antonio MD Anderson, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.
Two JAK inhibitors that are in clinical trials at the moment are momelitinib and pacritinib, both of which Mesa believes may become available in the near future. He says that momelitinib may have differentiation around cytopenias and anemia compared to other JAK inhibitors in this setting; pacritinib may be safe for patients with thrombocytopenia. He hopes to see multiple JAK inhibitors available for this patient population in the future so that physicians can tailor their treatment more appropriately in the first- and second-line settings.
If momelitinib and pacritinib are approved, the other agents will have the potential to be used as combination therapy, according to Mesa. Agents such as navitoclax (ABT-263) and luspatercept-aamt (Reblozyl) are options for possible combinations for patients with myelofibrosis, as well as fedratinib (Inrebic) and ruxolitinib (Jakafi), 2 other JAK inhibitors. He believes that optimizing JAK inhibition and complimentary drugs will be something to look forward to in the future of this setting.
<< View more resources and information regarding myeloproliferative neoplasms
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More